Funding
- NIH/NCI R01CA142859 (Role Co-I; PI: Conaway). Designs for phase I trials of combinations of agents. 2010-2013.
- NIH/NCI R01CA142859 (Role Co-I; PI: Conaway). Designs for phase I trials in heterogeneous groups. 2014-2019.
- NIH/NCI K25CA181638 (Role: PI). Phase I designs for combined immunotherapies in cancer. 2014-2019.
-
NIH/NCI R03CA238966 (Role: PI). Dose-finding designs for adoptive cell therapy trials. 2019-2021.
- NIH/NCI R01CA247932 (Role: PI). Dose finding designs for late-onset toxicities. 2021-2024.